The panel emphasizes the need for alignment and collaboration to enhance outcomes in hepatic encephalopathy (HE), stressing the importance of implementation science, APP education, and proactive screening for chronic liver disease and cirrhosis. They advocate for interdisciplinary meetings to optimize patient care and medication management, highlighting the increasing prevalence of complications related to cirrhosis in the US.
This series was supported by Salix Pharmaceuticals.